**STUDY IS NO LONGER ENROLLING**
The purpose of this research study is to test an investigational genital herpes-targeted immunotherapy. Investigational means the treatment is not approved by the FDA. The study will evaluate how your immune system is affected by the treatment and how safe the treatment is. The study will also look at the effects of the treatment on the rate of herpes simplex virus (HSV) shedding.
The study will enroll individuals who are between the ages of 18 and 60 and have a history of genital HSV. Participants must be willing to stop taking HSV-suppressive therapy for the duration of the study and must refrain from taking antiviral treatment during the swabbing periods of the study.
The study will last a little longer than 2 years (25 months) and will involve 16 on-site visits. It will involve blood draws, vaccinations, and the collection of genital swab samples.
To be eligible for this study you:
- Are between the ages of 18 and 60
- Received a diagnosis (>1 year ago) of genital HSV-2 infection and experience outbreaks
- Are willing to refrain from suppressive antiviral therapy for the duration of the study
Conditions which would prevent you from participating:
- A confirmed or suspected immunosuppressive condition
- A body mass index (BMI)of less than 18 OR more than 35
- Currently pregnant or breastfeeding or planning to become pregnant
Compensation:
Participants may receive up to $1,530 for participating in the study.
Clinic Location: Our clinic is located on the 11th floor of the Ninth and Jefferson Building at Harborview Medical Center. We are open Monday through Friday from 8:00am to 5:00pm.
Please contact us at 206-520-4340 or email us at vrc@uw.edu for more information.